Jun Activation Domain-binding Protein 1 Expression in Malignant Lymphoma of the Thyroid: Its Linkage to Degree of Malignancy and p27 Expression

Anticancer Research

Volumn 23, Issue 5 B, 2003, Pages 4121-4125

  Ito, Yasuhiro ^a   Yoshida, Hiroshi ^a   Matsuzuka, Fumio ^a   Matsuura, Nariaki ^b   Nakamura, Yasushi ^c   Nakamine, Hirokazu ^c   Kakudo, Kennichi ^c   Kuma, Kanji ^a   Miyauchi, Akira ^a  

^a KUMA HOSPITAL   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Immunohistochemistry; Jab1; Malignant lymphoma; Thyroid

Indexed keywords

BINDING PROTEIN; JUN ACTIVATION DOMAIN BINDING PROTEIN 1; KI 67 ANTIGEN; PROTEIN P27; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LYMPHOCYTIC INFILTRATION; LYMPHOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; THYROID CANCER; THYROIDITIS;

CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOCYTES, TUMOR-INFILTRATING; LYMPHOMA, B-CELL; LYMPHOMA, DIFFUSE; LYMPHOMA, FOLLICULAR; PEPTIDE HYDROLASES; THYROID NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0345303888     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Schlumberger MJ and Caillou B: Miscellaneous tumors of the thyroid. In: Thyroid. Lippincott Williams & Wilkins 8th Ed. pp944-948, 2001.
2. Matsuzuka F, Miyauchi A, Katayama S, Narabayashi I, Ikeda H, Kuma K and Sugawara M: Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. Thyroid 3: 93-99, 1993.
3. Matsuzuka F, Fukata S, Kuma K, Miyauchi A, Kakudo K and Sugawara M: Gene rearrangement of immunoglobulin as a marker of thyroid lymphoma. World J Surg 22: 558-561, 1998.
4. Sasaki K, Murakami T and Kawasaki M: The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Physiol 133: 579-584, 1987.
5. Claret FX, Hibi M, Dhut S, Toda T and Karin M: A new group of conserved coactivators that increase the specificity of AP-1 transcription factors. Nature 383: 453-457, 1996.
6. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM and Koff A: p27/Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 8: 9-22, 1994.
7. Tomoda K, Kubota Y and Kato J: Degradation of the cyclin-dependent-kinase inhibitor p27/kip1 is instigated by Jab1. Nature 398: 160-165, 1999.
8. Ito Y, Yoshida H, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Kuma K and Miyauchi A: Jun activation domain-binding protein 1 expression in thyroid neoplasm: its linkage to histology and p27 expression. Cancer Lett, in press.
9. Mathas S, Hinz M, Anagnostopoulos, Krappmann D, Lietz A, Jundt F, Bommert K, Mechta-Grigouriou F, Stein H, Dorken B and Scheidereit C: Aberrantly expressed c-Jun and Jun B are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J 21: 4104-4113, 2002.
10. Mao X, Orchard G, Lillington DM, Russell-Jones R, Young BD and Whittaker SJ: Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood 101: 1513-1519, 2003.
11. Wan M, Cao X, Wu Y, Bai S, Wu L, Shi X, Wang N and Cao X: Jab1 antagonizes TGF-beta signalling by inducing Smad4 degradation. EMBO Rep 3: 171-176, 2002.
12. Inman GF and Allday MJ: Resistance to TGF-beta 1 correlates with a reduction of TGF-beta type II receptor epression in Burkett's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines. J Gen Virol 81: 1567-1578, 2000.
13. Go JH: Decreased expression of TGF-beta type 2 receptor in primary B-cell lymphomas of the stomach. Pathol Res Pract 198: 333-337, 2002.
14. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K, Tai Y and Tokuda M: Jab1 expression is associated with inverse expression of p27/kip1 and poor prognosis in epithelial ovarian tumors. Clin Cancer Res 7: 4130-4135, 2001.
15. Korbonits M, Chahal HS, Kaltsas G, Jordan S, Urmanova Y, Khalimova Z, Harris PE, Farrell WE, Clarret FX and Gossman AB: Expression of phosphorylated p27/kip1 protein and jun activation domain-binding protein 1 in human pituitary tumors. J Clin Endocrinol Metab 87: 2635-2643, 2002.
16. Ciaparrone M, Yamamoto H, Yao Y, Sgambato A, Cattoretti G, Tomita N, Monden T, Rotterdam H and Weinstein IB: Localization and expression of p27KIP1 in multistage colorectal carcinogenesis. Cancer Res 58: 114-122, 1998.